Oppenheimer & Co. Inc. Takes $156,000 Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Oppenheimer & Co. Inc. bought a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 13,929 shares of the company’s stock, valued at approximately $156,000.

Other large investors have also modified their holdings of the company. Rinkey Investments acquired a new position in shares of ClearPoint Neuro in the 2nd quarter valued at $307,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in ClearPoint Neuro during the 2nd quarter worth $175,000. Price T Rowe Associates Inc. MD boosted its stake in ClearPoint Neuro by 7.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company’s stock worth $170,000 after purchasing an additional 1,813 shares during the period. Squarepoint Ops LLC acquired a new stake in ClearPoint Neuro during the 2nd quarter worth $549,000. Finally, Renaissance Technologies LLC boosted its stake in ClearPoint Neuro by 562.6% during the 2nd quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock worth $915,000 after purchasing an additional 144,088 shares during the period. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Price Performance

Shares of NASDAQ:CLPT opened at $11.84 on Friday. The stock has a market cap of $326.47 million, a P/E ratio of -17.15 and a beta of 1.10. The firm has a fifty day moving average price of $11.91 and a 200 day moving average price of $9.21. ClearPoint Neuro, Inc. has a 1-year low of $5.11 and a 1-year high of $14.13.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital increased their price target on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.